The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers.

Front Oncol · 2021 · PMC8674178 · PMID 34926309

Europe PMC DOI

hedged sentence

0.5460

closest p · 10.9× alpha

0.5460

boldest claim

The sentences

a favorable trendP =0.546not close (p > 0.1)

Objective response rate (ORR) to trastuzumab plus chemotherapy showed a favorable trend in patients with high TMB (75.0%, n=3/4) compared to patients with low TMB (59.3%, n=16/27) ( P =0.546).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.